Characteristics of patients with psoriatic arthritis treated with ustekinumab. Evidence from real-life clinical practice
Introduction. Psoriatic arthritis (PsA) is a chronic immunoinflammatory disease characterised by involvement of the skin, nail plates, joints, spine and entheses in the inflammatory process. The IL-12/IL-23 inhibitor ustekinumab (UST) is increasingly being used in psoriasis (Ps) and PsA.Aim of the s...
Main Authors: | Yu. L. Korsakova, E. Yu. Loginova, E. E. Gubar, T. V. Korotaeva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2021-01-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/5993 |
Similar Items
-
RESULTS OF USTEKINUMAB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS IN THE RUSSIAN FEDERATION ACCORDING TO THE DATA OF PSUMMIT 1 AND PSUMMIT 2
by: Yu. L. Korsakova, et al.
Published: (2015-04-01) -
CLINICAL EXPERIENCE WITH USTEKINUMAB IN THE TREATMENT OF EARLY PSORIATIC ARTHRITIS USING TREAT-TO-TARGET STRATEGY
by: E. Yu. Loginova, et al.
Published: (2015-09-01) -
Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry
by: E. E. Gubar, et al.
Published: (2021-10-01) -
Ustekinumab-induced chronic lymphocytic leukemia in a patient with psoriatic arthritis
by: Fusun Gediz, et al.
Published: (2021-02-01) -
A new integral enthesial-comorbididity index of psoriatic arthritis activity
by: Yulia L. Korsakova, et al.
Published: (2023-07-01)